Skip to content

Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates

Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01434810
Enrollment
447
Registered
2011-09-15
Start date
2011-11-30
Completion date
2013-09-30
Last updated
2019-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaundice, Neonatal

Keywords

Hyperbilirubinemia, Neonatal

Brief summary

The primary objective of this study is to determine the safety and efficacy of filtered sunlight phototherapy. Sunlight will be filtered by flexible (window-tinting) film. The subject population will be neonates born at Island Maternity Hospital, Lagos, Nigeria. The rationale for conducting the study is that in Nigeria, and other countries that may not have effective commercial light devices or have reliable access to electric power to operate them, filtered sunlight phototherapy might offer a safe and effective treatment for neonatal jaundice. Phase I of the study focused on the safety and efficacy of filtered sunlight phototherapy. Phase II of the study was a randomized controlled non-inferiority clinical trial comparing the efficacy of filtered sunlight phototherapy with conventional phototherapy.

Detailed description

Numerous studies from resource-limited countries suggest that severe neonatal jaundice (NNJ) represents the largest unrecognized cause of neonatal morbidity and mortality in the world. Several studies from Africa rank jaundice as a leading cause of death in newborn nurseries. In Nigeria, Owa and Osinaike reported that jaundice (14%) was the second leading cause of death, while Ugwu et al, found that mortality from severe jaundice was comparable to birth asphyxia but greater than sepsis in neonates \>24 hrs old to 7 days old. In Kenya, English et al reported NNJ as the third leading cause of both newborn admissions and deaths. Studies from Nigeria, Zimbabwe, Turkey, North Vietnam, Oman, and India listed acute bilirubin encephalopathy (ABE) and/or severe NNJ as a significant cause of morbidity, many of whom required exchange blood transfusion (EBT) in their nurseries. Unfortunately, phototherapy, as important as it is, may not be available to many infants with NNJ in these countries because of the lack of devices and/or of unreliable electrical power supply. Commercial phototherapy (PT) devices are expensive, often break down due to surges in electrical power, and are difficult to maintain due to unavailability of spare parts. Even where PT devices are available, most hospitals in these countries lack the resources to replace the fluorescent light bulbs at the recommended 2000-3000 hrs of use and simply leave ineffective tubes in place until they burn out. Moreover, very few hospitals have appropriate irradiance meters for monitoring the intensity of the blue light emitted by the lamps. In a recent study in Nigeria by Owa et al, none of the tested PT devices provided the level of irradiance required for intensive PT. Often, the only treatment a healthcare provider can suggest to the parents/guardians of jaundiced infants is to place their babies in sunlight. However, this practice is unsuitable due to several safety concerns. For instance, exposure to ultraviolet (UV) light may cause sunburn, while infrared (IR) light may cause the body to overheat. Moreover, the infant may lose body heat from the uncovered skin during treatment, with potential for dehydration. A safer, yet practical and economical, solution is needed, providing the basis for our proposal of filtered sunlight PT. The primary aims of this study were safety, efficacy and non-inferiority of filtered sunlight phototherapy compared to conventional phototherapy. Phase I of the study focused on the safety and efficacy of filtered sunlight phototherapy. Phase II focused on non-inferiority of efficacy as compared to conventional phototherapy while continuing to evaluate safety.

Interventions

Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.

Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.

Sponsors

Thrasher Research Fund
CollaboratorOTHER
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Non-inferiority trial comparing the two methods of phototherapy

Eligibility

Sex/Gender
ALL
Age
No minimum to 14 Days
Healthy volunteers
Yes

Inclusion criteria

Subjects will be eligible to participate in the study if all of the following conditions exist: 1. At time of birth, infant is \> 35 weeks gestation (or \> 2.2 kg if gestational age is not available 2. Infant is \< 14 days old at the time of enrollment 3. At time of enrollment, infant has an elevated TcB defined as 3 mg/dL below the level recommended for high-risk infants per AAP guidelines or higher 4. Parent or guardian has given consent for the infant to participate

Exclusion criteria

Subjects will be excluded from participation in the study if any of the following conditions exist at the time of enrollment: 1. Infants with a condition requiring referral for treatment not available at the hospital study site and/or conventional phototherapy unit. 2. Infants with a life-expectancy of \< 24 hours 3. Infants requiring oxygen therapy 4. Infants clinically dehydrated or sunburned 5. Infants with a temperature \< 35.5 or \> 38 degrees Centigrade 6. Infants with ABE on clinical exam 7. Infants meeting the criteria for EBT

Design outcomes

Primary

MeasureTime frameDescription
Safety of PhototherapyFour to ten daysFor a given treatment day, the phototherapy treatment was deemed safe if that infant on that day did not have to be withdrawn from treatment due to hypo- or hyperthermia, sunburn or dehydration. Therefore safety is reported as a percentage of the total treatment days (i.e. number of safe treatment days divided by total number of treatment days).
Efficacy of PhototherapyFour to ten daysFor a given evaluable treatment day, the phototherapy treatment was deemed effective if that infant on that day had a decrease in serum bilirubin level or (if \<72hrs old) an rate of increase of less than 0.2 mg/dL/h. Therefore efficacy is reported as a percentage of the evaluable treatment days (i.e. number of effective evaluable treatment days divided by total number of evaluable treatment days).

Secondary

MeasureTime frameDescription
Number of Participants Requiring Exchange Blood TransfusionFour to ten daysExchange blood transfusion required to lower the bilirubin level. Serum bilirubin will be measured twice daily during filtered sunlight or conventional phototherapy exposure, for an expected average of four days, and a maximum of ten days.

Countries

Nigeria

Participant flow

Participants by arm

ArmCount
Filtered Sunlight Phototherapy
Window tinting film will be used. Window tinting film for filtered sunlight phototherapy: Six hours per day of filtered sunlight phototherapy for 1 to 10 days.
224
Conventional Phototherapy
Infants will be randomized to conventional phototherapy (new arm) Conventional phototherapy: Conventional phototherapy unit will be used for infants randomized to this arm for 1 to 10 days.
223
Total447

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDid not receive treatment113
Overall StudyMissing data/received <5hr phototherapy127

Baseline characteristics

CharacteristicFiltered Sunlight PhototherapyConventional PhototherapyTotal
Age, Customized
Est'd gestational age
38 weeks38 weeks38 weeks
Sex: Female, Male
Female
102 Participants103 Participants205 Participants
Sex: Female, Male
Male
122 Participants120 Participants242 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 2240 / 223
serious
Total, serious adverse events
0 / 2240 / 223

Outcome results

Primary

Efficacy of Phototherapy

For a given evaluable treatment day, the phototherapy treatment was deemed effective if that infant on that day had a decrease in serum bilirubin level or (if \<72hrs old) an rate of increase of less than 0.2 mg/dL/h. Therefore efficacy is reported as a percentage of the evaluable treatment days (i.e. number of effective evaluable treatment days divided by total number of evaluable treatment days).

Time frame: Four to ten days

Population: The efficacy analysis was carried out on the 561 treatment days which were evaluable (see flow chart).

ArmMeasureValue (COUNT_OF_UNITS)
Filtered Sunlight PhototherapyEfficacy of Phototherapy232 treatment days
Conventional PhototherapyEfficacy of Phototherapy280 treatment days
Primary

Safety of Phototherapy

For a given treatment day, the phototherapy treatment was deemed safe if that infant on that day did not have to be withdrawn from treatment due to hypo- or hyperthermia, sunburn or dehydration. Therefore safety is reported as a percentage of the total treatment days (i.e. number of safe treatment days divided by total number of treatment days).

Time frame: Four to ten days

Population: Safety was assessed for all 593 days on which treatment was received, in all 433 participants who were treated.

ArmMeasureValue (COUNT_OF_UNITS)
Filtered Sunlight PhototherapySafety of Phototherapy268 treatment days
Conventional PhototherapySafety of Phototherapy325 treatment days
Secondary

Number of Participants Requiring Exchange Blood Transfusion

Exchange blood transfusion required to lower the bilirubin level. Serum bilirubin will be measured twice daily during filtered sunlight or conventional phototherapy exposure, for an expected average of four days, and a maximum of ten days.

Time frame: Four to ten days

Population: The need for exchange blood transfusion was assessed on all 447 enrolled participants.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Filtered Sunlight PhototherapyNumber of Participants Requiring Exchange Blood Transfusion0 Participants
Conventional PhototherapyNumber of Participants Requiring Exchange Blood Transfusion0 Participants

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026